Here is My Question:
What do you know about elezanumab and PPMS?
Elezanumab is a monoclonal antibody that binds to and inhibits RGMa (Repulsive Guidance Molecule) on Axons. The RGMa molecule inhibits axonal outgrowth following injury to the central nervous system which in turn limits repair and recovery. It is thought that inhibiting this molecule may enhance natural repair to damaged areas in the nervous system. It is being tested in patients with Primary Progressive MS (PPMS) but we have no results at present. You can find more information about the trial at Clinicaltrials.gov
Revere P (Rip) Kinkel, MDProfessor of Clinical Neurosciences
Director of the Multiple Sclerosis Program
Clinical Neurosciences Director
University of California San Diego
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.